A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies
type: MedicalStudy
description: A Phase 1 Study to Assess Safety and Tolerability of Odronextamab (REGN1979) an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, and Cemiplimab (REGN2810), an Anti-Programmed Death-1 Monoclonal Antibody in Patients With B-Cell Malignancies (CLIO-1)
status: ACTIVE_NOT_RECRUITING
study design: INTERVENTIONAL
phase: PHASE1
start date: 2016-01-11
end date: 2026-05-31
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT02651662
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: Regeneron Pharmaceuticals
study subject: Relapsed/Refractory Aggressive B-Cell Lymphoma
keywords: PHASE1
keywords: INTERVENTIONAL
keywords: ACTIVE_NOT_RECRUITING
keywords: Relapsed/Refractory Aggressive B-Cell Lymphoma

AI Analytics
type: Organization